Who are Flutiform 250/10 micrograms's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Budesonide/formoterol Turbuhaler, Budesonide / Formoterol, Symbicort Turbohaler without Turbo+, budesonide/formoterol Turbuhaler 320/9µg, FF, RELVAR/BREO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flutiform-250-10-micrograms.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Flutiform 250/10 micrograms — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Flutiform 250/10 micrograms (Flutiform 250/10 micrograms) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA). Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Flutiform 250/10 micrograms (Flutiform 250/10 micrograms) — Mundipharma Research Limited. Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Flutiform 250/10 micrograms TARGET	Flutiform 250/10 micrograms	Mundipharma Research Limited	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/formoterol Turbuhaler	Budesonide/formoterol Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide / Formoterol	Budesonide / Formoterol	Brigham and Women's Hospital	marketed	Inhaled corticosteroid / long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+	Symbicort Turbohaler without Turbo+	Istituto per la Ricerca e l'Innovazione Biomedica	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg	budesonide/formoterol Turbuhaler 320/9µg	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
FF	FF	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
RELVAR/BREO	RELVAR/BREO	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class)

Chiesi Farmaceutici S.p.A. · 5 drugs in this class
AstraZeneca · 5 drugs in this class
Mundipharma Research Limited · 4 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Milton S. Hershey Medical Center · 1 drug in this class
Mundipharma Korea Ltd · 1 drug in this class
SkyePharma AG · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Hospital, Antwerp · 1 drug in this class
Allergy and Asthma Center of El Paso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flutiform 250/10 micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/flutiform-250-10-micrograms. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing